11![U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived](https://www.pdfsearch.io/img/f916c88dc7ac512df24651ddebb63d6e.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
12![Best Buy Drugs Report on Drugs to Treat Enlarged Prostate Best Buy Drugs Report on Drugs to Treat Enlarged Prostate](https://www.pdfsearch.io/img/88f7e1b035639d1902dbed0e33d3c241.jpg) | Add to Reading ListSource URL: consumerhealthchoices.orgLanguage: English - Date: 2013-07-06 14:31:50
|
---|
13![Recent Publications from Physicians at the Iris Cantor Men’s Health Center: Jamzadeh AE, Xie D, Laudano M, Seklehner S, Elterman DS, Shtromvaser L, Lee R, Kaplan SA, Te AE, and Chughtai B. Urodynamic characterization o Recent Publications from Physicians at the Iris Cantor Men’s Health Center: Jamzadeh AE, Xie D, Laudano M, Seklehner S, Elterman DS, Shtromvaser L, Lee R, Kaplan SA, Te AE, and Chughtai B. Urodynamic characterization o](https://www.pdfsearch.io/img/1b4c2cfb8ad36af4e866d4aa325b9f52.jpg) | Add to Reading ListSource URL: nyp.orgLanguage: English - Date: 2013-08-08 10:44:37
|
---|
14![Microsoft Word - BPH Treatment Mar 10.doc Microsoft Word - BPH Treatment Mar 10.doc](https://www.pdfsearch.io/img/0200c33e6606360fc8b7e4a1324a89e7.jpg) | Add to Reading ListSource URL: www.oregon.govLanguage: English - Date: 2014-07-15 14:00:38
|
---|
15![Microsoft Word - Avodart_PM _2013-09-12_ Microsoft Word - Avodart_PM _2013-09-12_](https://www.pdfsearch.io/img/b4a04f2fdd73cf8684f82db6d321f665.jpg) | Add to Reading ListSource URL: www.gsk.caLanguage: English - Date: 2013-09-23 16:01:05
|
---|
16![JALYN may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.3) Do not use JALYN with strong inhibitors of cytochrome P450 (C JALYN may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.3) Do not use JALYN with strong inhibitors of cytochrome P450 (C](https://www.pdfsearch.io/img/9f1772561de92cd46b95a5977ee1e487.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-04-29 16:52:22
|
---|
17![ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART.](https://www.pdfsearch.io/img/29b1967ec6d2eaba7c91a068b7ae6dd9.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2013-05-01 16:59:55
|
---|
18![-------------------------------CONTRAINDICATIONS-----------------------• Pregnancy and women of childbearing potential. (4, 5.4, 8.1) • -------------------------------CONTRAINDICATIONS-----------------------• Pregnancy and women of childbearing potential. (4, 5.4, 8.1) •](https://www.pdfsearch.io/img/086c747826fa2bdce024a99260f68525.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-06-10 14:49:27
|
---|
19![CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for:](https://www.pdfsearch.io/img/9ebdcbefd9dfc33252c73415d6f37fc5.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-02-03 14:44:20
|
---|
20![• Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4) • Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4)](https://www.pdfsearch.io/img/da0b37383b9b4d85f7763990d8ca62cf.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-09-09 19:11:22
|
---|